Xiaohu Zhang

发表

Discovery of Novel and Selective Adenosine A2A Receptor Antagonists for Treating Parkinson's Disease through Comparative Structure-Based Virtual Screening

Youyong Li, T. Hou, Xuechu Zhen, 2017, J. Chem. Inf. Model..

Discovery of potent and novel smoothened antagonists via structure-based virtual screening and biological assays.

Sheng Tian, L. Luo, Xiaohu Zhang, 2018, European journal of medicinal chemistry.

Early glycolytic reprogramming controls microglial inflammatory activation

Xuechu Zhen, L. Zheng, Huicui Yang, 2021, Journal of neuroinflammation.

Rational design of highly selective spleen tyrosine kinase inhibitors.

Johannes C. Hermann, A. Kuglstatter, K. Luk, 2012, Journal of medicinal chemistry.

Structural optimization on a virtual screening hit of smoothened receptor.

Youyong Li, Sheng Tian, L. Luo, 2019, European journal of medicinal chemistry.

Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity.

Zhijian Sun, Sheng Tian, L. Luo, 2017, ACS chemical neuroscience.

GYY4137, an H2S Slow-Releasing Donor, Prevents Nitrative Stress and α-Synuclein Nitration in an MPTP Mouse Model of Parkinson’s Disease

Xiaohu Zhang, Jiyue Zheng, Chun-Feng Liu, 2017, Front. Pharmacol..

Design, synthesis, and evaluation of potent RIPK1 inhibitors with in vivo anti-inflammatory activity.

T. Yang, Sheng Tian, Jingrui Wang, 2021, European journal of medicinal chemistry.

Design, synthesis, and evaluation of pyrrolidine based CXCR4 antagonists with in vivo anti-tumor metastatic activity.

L. Luo, Xu Wang, Xiaohu Zhang, 2020, European journal of medicinal chemistry.

Design, synthesis, and structure-activity-relationship of a novel series of CXCR4 antagonists.

L. Luo, C. Fu, Xu Wang, 2018, European journal of medicinal chemistry.

Scaffold hopping approach to a new series of smoothened antagonists.

Zhijian Sun, Xiaohu Zhang, Wenfeng Lu, 2014, Bioorganic & medicinal chemistry letters.

Knockdown of milk‐fat globule EGF factor‐8 suppresses glioma progression in GL261 glioma cells by repressing microglial M2 polarization

Xuechu Zhen, L. Zheng, Huicui Yang, 2020, Journal of cellular physiology.

Synthesis and characterization of potent RIPK3 inhibitors based on a tricyclic scaffold.

Sheng Tian, Xiaohu Zhang, Haikuo Ma, 2022, Future medicinal chemistry.

Design, synthesis, and evaluation of novel CXCR4 antagonists based on an aminoquinoline template.

L. Luo, Xiaohu Zhang, Haikuo Ma, 2020, Bioorganic chemistry.

Discovery of NBI-77860/GSK561679, a potent corticotropin-releasing factor (CRF1) receptor antagonist with improved pharmacokinetic properties.

D. Grigoriadis, S. Hoare, D. Slee, 2010, Bioorganic & medicinal chemistry letters.

2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 2. Reduction of hERG activity, observed species selectivity, and structure-activity relationships.

J. Díaz, S. Lechner, D. Slee, 2008, Journal of medicinal chemistry.

Discovery of a Potent RIPK3 Inhibitor for the Amelioration of Necroptosis-Associated Inflammatory Injury

Jingrui Wang, Xiaohu Zhang, Haikuo Ma, 2020, Frontiers in Cell and Developmental Biology.

Design and Synthesis of Tricyclic Imidazo[4,5- b ]pyridin-2-ones as Corticotropin-Releasing Factor-1 Antagonists

Zhiqian Guo, D. Grigoriadis, B. Dyck, 2005 .

Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core.

Zhiqian Guo, D. Grigoriadis, B. Dyck, 2005, Journal of medicinal chemistry.

2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 1. Structure-activity relationships and optimization of heterocyclic substituents.

J. Díaz, S. Lechner, D. Slee, 2008, Journal of medicinal chemistry.

Early glycolytic reprogramming controls microglial inflammatory activation

Xuechu Zhen, L. Zheng, Huicui Yang, 2020, Journal of Neuroinflammation.

Anti-inflammatory effects of glaucocalyxin B in microglia cells.

Fali Zhang, Ping Gan, Jian Zhang, 2015, Journal of pharmacological sciences.

Design, synthesis and evaluation of a series of non-steroidal anti-inflammatory drug conjugates as novel neuroinflammatory inhibitors.

Xuechu Zhen, Xuechu Zhen, L. Zheng, 2015, International immunopharmacology.

Design, synthesis, and structure--activity-relationship of tetrahydrothiazolopyridine derivatives as potent smoothened antagonists.

Zhijian Sun, L. Luo, Xiaohu Zhang, 2015, European journal of medicinal chemistry.

Design, synthesis, and evaluation of novel porcupine inhibitors featuring a fused 3-ring system based on the 'reversed' amide scaffold.

Shuaishuai Chen, L. Luo, Xiaohu Zhang, 2016, Bioorganic & medicinal chemistry.

Development of Adenosine A2A Receptor Antagonists for the Treatment of Parkinson's Disease: A Recent Update and Challenge.

Xuechu Zhen, Xiaohu Zhang, Jiyue Zheng, 2018, ACS chemical neuroscience.

A novel RIPK1 inhibitor reduces GVHD in mice via a nonimmunosuppressive mechanism that restores intestinal homeostasis

Feng Ma, Sheng Tian, Xiaohu Zhang, 2022, Blood.

Discovery, optimization and evaluation of isothiazolo[5,4-b]pyridine derivatives as RIPK1 inhibitors with potent in vivo anti-SIRS activity.

Sheng Tian, Xiaohu Zhang, Haikuo Ma, 2022, Bioorganic chemistry.

Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis

Xiaohu Zhang, Hongjiang Zhang, Yangxin Li, 2019, Cell Death & Disease.

Ring closure strategy leads to potent RIPK3 inhibitors.

Xiaohu Zhang, Haikuo Ma, S. He, 2021, European journal of medicinal chemistry.

Design, synthesis, and structure-activity relationship of novel RIPK2 inhibitors.

Jingrui Wang, Xiaohu Zhang, S. He, 2022, Bioorganic & medicinal chemistry letters.

Discovery of a 6-(pyridin-3-yl)benzo[d]thiazole template for optimization of hedgehog and PI3K/AKT/mTOR dual inhibitors.

Zhijian Sun, Sheng Tian, L. Luo, 2015, Bioorganic & medicinal chemistry letters.

Design, Synthesis, and Characterization of Novel CXCR4 Antagonists Featuring Cyclic Amines

Sheng Tian, L. Luo, C. Fu, 2020, ChemMedChem.

Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists.

J. Díaz, S. Lechner, D. Slee, 2008, Bioorganic & medicinal chemistry letters.

Cyclopamine, a naturally occurring alkaloid, and its analogues may find wide applications in cancer therapy.

Xiaohu Zhang, Haikuo Ma, Huan-qiu Li, 2013, Current topics in medicinal chemistry.

Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis

Xiaohu Zhang, Hongjiang Zhang, Yangxin Li, 2019, Cell Death & Disease.

Design, synthesis, and evaluation of potent Wnt signaling inhibitors featuring a fused 3-ring system.

Zhijian Sun, L. Luo, Xiaohu Zhang, 2016, European journal of medicinal chemistry.

Design and synthesis of tricyclic imidazo[4,5-b]pyridin-2-ones as corticotropin-releasing factor-1 antagonists.

Zhiqian Guo, D. Grigoriadis, B. Dyck, 2005, Journal of Medicinal Chemistry.

Antiviral activity of PHA767491 against human herpes simplex virus in vitro and in vivo

C. Zheng, Xiaohu Zhang, Qiang Huang, 2017, BMC Infectious Diseases.

Synthesis and evaluation of dihydrofuro[2,3-b]pyridine derivatives as potent IRAK4 inhibitors.

Sheng Tian, Xiaohu Zhang, Haikuo Ma, 2023, European journal of medicinal chemistry.

Design, synthesis, evaluation and optimization of potent IRAK4 inhibitors alleviating production of inflammatory cytokines in LPS-induced SIRS model.

Sheng Tian, Xiaohu Zhang, Haikuo Ma, 2023, Bioorganic chemistry.

Discovery of a novel RIPK2 inhibitor for the treatment of inflammatory bowel disease.

Xin Chen, Xiaohu Zhang, Xue-bo Sun, 2023, Biochemical pharmacology.

Discovery of a potent hedgehog pathway inhibitor capable of activating caspase8-dependent apoptosis.

Qin Chen, L. Luo, Xiaohu Zhang, 2018, Journal of pharmacological sciences.

Discovery and characterization of a potent Wnt and hedgehog signaling pathways dual inhibitor.

L. Zheng, Shuaishuai Chen, L. Luo, 2018, European journal of medicinal chemistry.

Optimization of 6-heterocyclic-2-(1H-pyrazol-1-yl)-N-(pyridin-2-yl)pyrimidin-4-amine as potent adenosine A2A receptor antagonists for the treatment of Parkinson's disease.

Xuechu Zhen, LinLang Li, Xiaohu Zhang, 2014, ACS chemical neuroscience.

Replacement of amide with bioisosteres led to a new series of potent adenosine A2A receptor antagonists.

Xuechu Zhen, Xiaohu Zhang, Haikuo Ma, 2014, Bioorganic & medicinal chemistry letters.

Structural optimization of aminopyrimidine-based CXCR4 antagonists.

Sheng Tian, Xiaotian Sun, L. Luo, 2019, European journal of medicinal chemistry.

Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.

J. Díaz, S. Lechner, D. Slee, 2008, Journal of medicinal chemistry.

Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.

Johannes C. Hermann, John Menke, A. Kuglstatter, 2013, Journal of medicinal chemistry.